Table 2.
Peptides identified or engineered for cancer therapy using phages.
| Peptide Sequence | Target | Biological Applications | Phage/Phage Library | References |
|---|---|---|---|---|
| DKSEKFARDA | GM-CSF | Colorectal cancer | M13 | [113] |
| CDCRGDCFC | TAA | Breast cancer | T7 | [127] |
| EADPTGHSY | MAGE A1 | Antitumor | Fd | [147] |
| ATWLPPR | VEGF | Anti-angiogenesis | M13 | [150] |
| DTDWVRMRDSAR, VPGWSQAFMALA | EGFR | Lung cancer | Ph.D-12 | [151] |
| HTMYYHHYQHHL | VEGF | Breast carcinoma | Ph.D-12 | [152] |
| KIFGSLAFL | HER2 | Tubo tumor | Lambda | [153,154] |
| GLYDGMEHL, FLWGPRALV | MAGE-A10, MAGE A3 | Antitumor | Fd | [155] |
| LSPPRYP | FGFR | Melanoma | Ph.D-7 | [156] |
| VYMSPF | FGFR1 | Anti-angiogenesis | 6-mer phage | [157] |
| ACSLNHTVNC, ACSAKTTSAC | FGFR1 | Anti-angiogenesis | Ph.D-C7C | [158] |
| HSQAAVP | FGF8b | Prostate cancer | Ph.D-7 | [159] |
| QHYNIVNTQSRV | EGFR | Lung carcinoma | M13 | [160] |
| TRTKLPRLHLQS | TAA | Antitumor | M13 | [161] |
| KRTGQYKL | FGFR | Anti-angiogenesis | M13 | [162] |